Ranbaxy Slated For Generic Nexium Approval
This article was originally published in PharmAsia News
U.S. FDA Feb. 7 granted Ranbaxy a tentative approval for 20 mg and 40 mg delayed-release capsules of esomeprazole, a generic version of AstraZeneca's Nexium. The proton pump inhibitor is scheduled to lose U.S. exclusivity in October 2009. AstraZeneca reported $3.4 billion in U.S. Nexium sales for 2007. Gurgaon, India-based Ranbaxy claims it has first-to-file status for esomeprazole, which would give the company 180-day marketing exclusivity
You may also be interested in...
MUMBAI - India's top drug maker Ranbaxy Laboratories could be ready to team up with Israel's Teva Pharmaceuticals for an "at risk" launch of a generic version of AstraZeneca's heartburn blockbuster Nexium (esomeprazole), following tentative U.S. approval last month, Indian analysts say
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).